Jonathan R Skirko1, Kathryn T James2, Louis P Garrison3, Edward M Weaver4,5. 1. Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of Utah, Salt Lake City. 2. Comparative Effectiveness, Cost and Outcomes Research Center, University of Washington, Seattle. 3. Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle. 4. Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle. 5. Surgery Service, Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
Abstract
Importance: With the increasing emphasis on economic evaluations, there is a need for additional methods of measuring patient utility in the obstructive sleep apnea population. Objective: To develop and validate a utility scoring algorithm for a sleep apnea-specific quality-of-life instrument. Design, Setting, and Participants: Development and validation were conducted at 2 tertiary referral sleep centers and associated sleep clinics and included patients with newly diagnosed obstructive sleep apnea from a randomized clinical trial and an associated observational cohort study. Baseline participants were randomly divided into a model development group (60%) and a cross-validation group (40%). Main Outcomes and Measures: Utility scoring of the Symptoms of Nocturnal Obstruction and Related Events (SNORE-25) was mapped from the SF-6D utility index through multiple linear regression in the development sample using the Akaike information criterion to determine the best model. Results: A total of 500 participants (development, n = 300; validation, n = 200) were enrolled; the analyzed sample of 500 participants included 295 men (59%), and the mean (SD) age was 48.6 (12.8) years, with a range of 18 to 90 years. The mean (SD) SF-6D utility among participants with untreated sleep apnea was 0.61 (0.08; range, 0.40-0.85) with similar utility across sleep apnea severity groups. The best-fit model (the SNORE Utility Index) was the natural log conversion of the instrument subscales (r2 = 0.32 in the development sample). The SNORE Utility Index retained this association within the validation sample (r2 = 0.33). Conclusions and Relevance: The SNORE Utility Index provides a validated, disease-specific, preference-weighted utility instrument that can be used in future studies of patients with obstructive sleep apnea.
RCT Entities:
Importance: With the increasing emphasis on economic evaluations, there is a need for additional methods of measuring patient utility in the obstructive sleep apnea population. Objective: To develop and validate a utility scoring algorithm for a sleep apnea-specific quality-of-life instrument. Design, Setting, and Participants: Development and validation were conducted at 2 tertiary referral sleep centers and associated sleep clinics and included patients with newly diagnosed obstructive sleep apnea from a randomized clinical trial and an associated observational cohort study. Baseline participants were randomly divided into a model development group (60%) and a cross-validation group (40%). Main Outcomes and Measures: Utility scoring of the Symptoms of Nocturnal Obstruction and Related Events (SNORE-25) was mapped from the SF-6D utility index through multiple linear regression in the development sample using the Akaike information criterion to determine the best model. Results: A total of 500 participants (development, n = 300; validation, n = 200) were enrolled; the analyzed sample of 500 participants included 295 men (59%), and the mean (SD) age was 48.6 (12.8) years, with a range of 18 to 90 years. The mean (SD) SF-6D utility among participants with untreated sleep apnea was 0.61 (0.08; range, 0.40-0.85) with similar utility across sleep apnea severity groups. The best-fit model (the SNORE Utility Index) was the natural log conversion of the instrument subscales (r2 = 0.32 in the development sample). The SNORE Utility Index retained this association within the validation sample (r2 = 0.33). Conclusions and Relevance: The SNORE Utility Index provides a validated, disease-specific, preference-weighted utility instrument that can be used in future studies of patients with obstructive sleep apnea.
Authors: Thomas M Atkinson; Barry D Rosenfeld; Laura Sit; Tito R Mendoza; Mike Fruscione; Dawn Lavene; Mary Shaw; Yuelin Li; Jennifer Hay; Charles S Cleeland; Howard I Scher; William S Breitbart; Ethan Basch Journal: J Pain Symptom Manage Date: 2010-12-04 Impact factor: 3.612
Authors: Francisco Campos-Rodriguez; Nicolas Peña-Griñan; Nuria Reyes-Nuñez; Ines De la Cruz-Moron; Jose Perez-Ronchel; Francisco De la Vega-Gallardo; Ana Fernandez-Palacin Journal: Chest Date: 2005-08 Impact factor: 9.410
Authors: Kevin J Finkel; Adam C Searleman; Heidi Tymkew; Christopher Y Tanaka; Leif Saager; Elika Safer-Zadeh; Michael Bottros; Jacqueline A Selvidge; Eric Jacobsohn; Debra Pulley; Stephen Duntley; Colleen Becker; Michael S Avidan Journal: Sleep Med Date: 2009-01-30 Impact factor: 3.492
Authors: Martina Schmidlin; Karsten Fritsch; Felix Matthews; Robert Thurnheer; Oliver Senn; Konrad E Bloch Journal: Respiration Date: 2009-05-27 Impact factor: 3.580